Abstract

Because of increasing resistance of malaria parasites to artemisinin and partner drugs, especially in Southeast Asia, new antimalarials are needed. In a multicenter, open-label, phase 2, manufacturer-sponsored trial, investigators in Thailand and Vietnam assessed the antimalarial efficacy, safety, and pharmacokinetic profile of KAF156 (an imidazolopiperazine). This agent has activity against blood stages and the preerythrocytic liver parasite stages. They enrolled adults with uncomplicated Plasmodium vivax or Plasmodium falciparum malaria . Cohorts 1 and …

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call